Atherosclerotic plaques that cause stroke and myocardial infarction are characterized by increased microvascular permeability and inflammation. Dynamic contrast enhanced (DCE) MRI has been proposed as a method to quantify vessel wall microvascular permeability in vivo. Until now, most DCE-MRI studies have been limited to 2 dimensional (2D), multi-slice imaging. While providing the high-spatial resolution required to image the arterial vessel wall, these approaches do not allow quantifying plaque permeability with extensive anatomical coverage, an essential feature when imaging heterogeneous diseases, such as atherosclerosis. To our knowledge, we present the first systematic evaluation of 3 dimensional (3D), high-resolution, DCE-MRI for the extensive quantification of plaque permeability along an entire vascular bed, with validation in atherosclerotic rabbits. We compare two acquisitions: 3D turbo field echo (TFE) with MSDE preparation (motion sensitized driven equilibrium), and 3D TSE (turbo spin echo). We find 3D TFE DCE-MRI to be superior to 3D TSE DCE-MRI in terms of temporal stability metrics. Both sequences showed good intra and inter-observer reliability, and significant correlation with ex vivo permeability measurements by Evans Blue near infra-red fluorescence (NIRF). Additionally, we explore the feasibility of using compressed sensing to accelerate 3D DCE-MRI of atherosclerosis, to improve its temporal resolution and therefore the accuracy of permeability quantification. Using retrospective under-sampling and reconstructions we show that compressed sensing alone may allow accelerating 3D DCE-MRI up to 4 folds. We anticipate that the development of high spatial resolution 3D DCE-MRI with prospective compressed sensing acceleration may allow for the more accurate and extensive quantification of atherosclerotic plaque permeability along an entire vascular bed. We foresee that this approach may allow for the comprehensive and accurate evaluation of plaque permeability in patients, and may be a useful tool to assess therapeutic response to approved and novel drugs for cardiovascular disease.